Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice

File(s)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.pdf (447.46 KB)

Published version

Show more

Author(s)

Fletcher, Sophie V

Jones, Mark G

Renzoni, Elizabeth A

Parfrey, Helen

Hoyles, Rachel K

more

Type

Journal Article

Abstract

In IPF, commencement of antifibrotic therapy in patients with preserved lung volume may increase the duration of therapy http://ow.ly/4HeM30lFS67.

Show more

Date Issued

2018-10-19

Date Acceptance

2018-08-25

Citation

ERJ Open Research, 2018, 4 (4)

URI

http://hdl.handle.net/10044/1/64314

DOI

https://www.dx.doi.org/10.1183/23120541.00049-2018

ISSN

2312-0541

Publisher

European Respiratory Society

Journal / Book Title

ERJ Open Research

Volume

4

Issue

4

Copyright Statement

©ERS 2018. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0 (https://creativecommons.org/licenses/by-nc/4.0/)

Identifier

https://www.ncbi.nlm.nih.gov/pubmed/30364342

PII: 00049-2018

Publication Status

Published

Coverage Spatial

England

Date Publish Online

2018-10-19